McDonald C F, Atkins R C
Department of Respiratory Medicine, Prince Henry's Hospital, Melbourne, Australia.
Chest. 1990 Oct;98(4):881-5. doi: 10.1378/chest.98.4.881.
Macrophages are thought to play an important immune effector cell role in antitumor host defense. It remains unclear whether PAM antitumor activity in patients with lung cancer is normal or impaired. We examined PAM cytostasis in patients with lung cancer and in control subjects and determined whether the in vitro PAM response could be enhanced by gamma-interferon. Nineteen patients with primary lung carcinoma and 15 control patients underwent BAL. Five patients with cancer underwent lavage of both lungs to assess whether any abnormality found related to tumor proximity or was part of a more generalized defect. Cytostatic activity was assessed by measuring inhibition of incorporation of tritiated thymidine into the target cell U937. There was a significant difference in baseline cytostatic activity between patients with cancer (mean +/- SE, 59 +/- 7 percent) and control patients (92 +/- 2 percent) (p less than 0.0002). The increase in cytostatic function after stimulation with gamma-interferon (1,250 units/ml) was higher in the group with cancer (28 +/- 5 percent increase from baseline) than in controls (5 +/- 1 percent) (p less than 0.0005). Cytostasis after stimulation was not significantly different between the groups. In the bilaterally lavaged group, baseline cytostatic activity was not different between cancerous and noncancerous lungs and was again significantly lower than in control subjects. These results indicate (a) that PAM baseline cytostatic activity in patients with cancer is lower than in controls, (b) that gamma-interferon can significantly augment cytostatic function in patients with cancer, to levels comparable with those achievable in control patients, and (c) that the PAM abnormality is part of a generalized immune defect in lung cancer and does not simply reflect a local response to the carcinoma. It may be inferred from these results that PAMs from patients with primary lung cancer are not fully stimulated in vivo and that a defect of T cell lymphokine production may underlie the macrophage dysfunction.
巨噬细胞被认为在抗肿瘤宿主防御中发挥重要的免疫效应细胞作用。肺癌患者中肺泡巨噬细胞(PAM)的抗肿瘤活性是正常还是受损仍不清楚。我们检测了肺癌患者和对照受试者的PAM细胞抑制作用,并确定γ干扰素是否能增强体外PAM反应。19例原发性肺癌患者和15例对照患者接受了支气管肺泡灌洗(BAL)。5例癌症患者对双肺进行灌洗,以评估所发现的任何异常是与肿瘤邻近有关还是更广泛缺陷的一部分。通过测量氚标记胸腺嘧啶核苷掺入靶细胞U937的抑制率来评估细胞抑制活性。癌症患者(均值±标准误,59±7%)和对照患者(92±2%)的基线细胞抑制活性存在显著差异(p<0.0002)。γ干扰素(1250单位/ml)刺激后,癌症组的细胞抑制功能增加(较基线增加28±5%)高于对照组(5±1%)(p<0.0005)。刺激后的细胞抑制作用在两组之间无显著差异。在双侧灌洗组中,癌肺和非癌肺的基线细胞抑制活性无差异,且再次显著低于对照受试者。这些结果表明:(a)癌症患者的PAM基线细胞抑制活性低于对照组;(b)γ干扰素可显著增强癌症患者的细胞抑制功能,使其达到与对照患者相当的水平;(c)PAM异常是肺癌中广泛免疫缺陷的一部分,并非简单反映对癌症的局部反应。从这些结果可以推断,原发性肺癌患者的PAM在体内未被充分刺激,T细胞淋巴因子产生缺陷可能是巨噬细胞功能障碍的基础。